The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.

How this report will benefit you
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 171-page report you will receive 69 tables and 97 figures– all unavailable elsewhere.
  • The 171-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2029

This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
  • Antifibrotics
  • Tyrosine Kinase Inhibitors
  • Anti-inflammatory Drugs
  • Immunosuppressants
  • Other MoA

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
  • Innovator Drugs
  • Off-label Drugs

This report provides individual revenue forecasts to 2029 for these national markets:
  • US
  • Japan
  • EU5: Germany, France, the UK, Italy, Spain
  • Rest of World

This report provides individual revenue forecasts to 2029 for these marketed drugs:
  • Esbriet
  • Ofev

Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
  • Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets
  • Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
  • Epidemiology of Idiopathic Pulmonary Fibrosis by gender
  • Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
  • Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
  • A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market

Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
  • Actelion
  • Afferent Pharmaceuticals
  • Asahi Kasei Pharma
  • Bellerophon Therapeutics
  • Biogen
  • Boehringer Ingelheim
  • FibroGen
  • Galapagos
  • Galecto Biotech
  • Genentech
  • Global Blood Therapeutics
  • GSK
  • Kadmon Pharmaceuticals
  • LTT Bio-Pharma
  • MediciNova
  • Merck
  • Moerae
  • Pacific Therapeutics
  • Promedior
  • ProMetic Life Sciences
  • Roche
  • Sanofi
  • Teva
  • Zai Lab